Business Wire

Swiss-based Non-profit GARDP Supports the Development of Debiopharm’s New Potential Treatment for Gonorrhoea

Share

The Global Antibiotic Research & Development Partnership (GARDP) and the Swiss-based global biopharmaceutical company Debiopharm have signed a memorandum of understanding to develop Debio 1453, a novel compound representing a new antibiotic class that targets Neisseria gonorrhoeae. Multidrug-resistant strains of N. gonorrhoeae have emerged globally, limiting treatment options and elevating this pathogen to the high-priority category on the World Health Organization’s Bacterial Priority Pathogen List. Such pathogens present distinct public health challenges that urgently require new treatments.

“Antibiotic-resistant gonorrhoea represents a serious threat to sexual and reproductive health,” said Morgane Vanbiervliet, Manager of Market Intelligence & Business Development, Infectious Diseases, Debiopharm. “Debio 1453 shows encouraging pre-clinical efficacy against resistant strains of N. gonorrhoeae. We are eager to continue to develop this compound in collaboration with GARDP.”

Debiopharm has completed the preclinical development of Debio 1453 with ongoing support from the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X). The MOU between Debiopharm and GARDP now sets the stage for a new partnership to develop the compound for regulatory approval and help make the final product available and affordable to treat patients worldwide.

“We are very pleased to lay the groundwork for a future partnership with Debiopharm,” said Yann Ferrisse, Director of Business Development at GARDP. “In line with our 2024-2028 strategy, we will continue to identify new opportunities like Debio 1453 to develop and make available treatments for gonorrhoea and other public health threats.”

Innovative approaches are necessary to treat N. gonorrhoeae, which has gradually developed resistance to many classes of antibiotics used to treat gonorrhoea infections. A single muscular injection of ceftriaxone is now the last available recommended treatment globally. Recent reports of outbreaks of ceftriaxone-resistant “super gonorrhoea” have heightened the urgency for new antibiotic treatments.

Debio 1453 shows promising activity against ceftriaxone-resistant and other multidrug-resistant strains of N. gonorrhoeae. The compound uses a unique and novel mechanism of action to target the FabI enzyme, on which N. gonorrhoeae relies for its growth and survival. In studies thus far, no cross-resistance to any antibiotic class has been observed.

With more than 82 million new gonorrhoea infections occurring globally each year, gonorrhoea is the third most common sexually transmitted infection. It can cause serious, lifelong consequences in men and women, and can amplify the spread of HIV in high-prevalence settings. When left untreated in women, gonorrhoea can lead to pelvic inflammatory disease that elevates the risk of complications in pregnancy, including the likelihood of ectopic pregnancies and infertility. Gonorrhoea can also be transmitted during birth to babies, who in turn can have health problems like gonococcal conjunctivitis.

Debiopharm

Debiopharm aims to develop innovative therapies that target high unmet medical needs primarily in oncology and bacterial infections. Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds and technologies for in-licensing, clinically demonstrate their safety and efficacy, and then hand stewardship to large pharmaceutical commercialization partners to maximize patient access globally.

For more information, please visit www.debiopharm.com

We’re on X. Follow us @DebiopharmNews at http://twitter.com/DebiopharmNews

GARDP

We are a not-for-profit global health organization driven to protect people from the rise and spread of drug-resistant infections, one of the biggest threats to us all. By forging the public and private partnerships that matter, we develop and make accessible antibiotic treatments for people who need them. We receive vital support from the governments of Canada, Germany, Japan, Monaco, the Netherlands, Switzerland, the United Kingdom, the Canton of Geneva, the European Union, as well as the Bill & Melinda Gates Foundation, Global Health EDCTP3, GSK, the RIGHT Foundation, the South African Medical Research Council (SAMRC) and Wellcome. We are GARDP, the Global Antibiotic Research & Development Partnership. www.gardp.org

*CARB-X is a global non-profit partnership dedicated to supporting early-stage antibacterial research and development to address the rising threat of drug-resistant bacteria. Research reported in this press release is supported by CARB-X. CARB-X funding for this research is supported by federal funds from the U.S. Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority; under agreement number: 75A50122C00028, and by awards from Wellcome (WT224842), and Germany’s Federal Ministry of Education and Research (BMBF). The content of this press release is solely the responsibility of the authors and does not necessarily represent the official views CARB-X or its funders.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250114291716/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Align Partners Urges Governance and Capital Allocation Improvements at Coway Co., Ltd.21.1.2025 13:00:00 CET | Press release

Despite holding only 25%, Netmarble’s outsized influence over Coway casts serious doubt on how effectively conflicts are managedAlign Partners urges capital structure optimization and stronger governance at Coway to ensure all shareholders’ interests are protected – not only that of NetmarbleAlign Partners’ Presentation is available at https://www.bside.ai/coway/feed/1206 Align Partners Capital Management Inc. ("Align Partners"), a shareholder of Coway Co., Ltd. (KRX: 021240) ("Coway" or the “Company”) owning 2.8%, has published a presentation calling for improvements in Coway’s governance and capital allocation. Netmarble Corp. (“Netmarble”), with a 25.1% stake, wields disproportionate control over Coway. This influence is entrenched through its founder serving as Executive Chair, a former Netmarble executive as CEO, and a director nomination process overseen by Netmarble, raising serious governance concerns. Coway’s governance structure, with obvious conflicts of interest, has failed

Privacy Budgets Set to Decrease in 2025, New Research From ISACA Reveals21.1.2025 13:00:00 CET | Press release

Companies investing in privacy are seeing benefits in appropriately staffed teams and decreased skills gaps More than two in five (45%) privacy professionals in Europe believe that their organisation’s privacy budget is underfunded. This marks an increase from 41% in 2024 – and more than half (54%) expect budgets to decrease further in 2025. That’s according to new research from ISACA, the leading global professional association helping individuals and organisations in their pursuit of digital trust. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250121719239/en/ ISACA’s annual privacy study reveals insights into data breaches, staffing, budgets, training and obstacles from more than 1,600 global professionals, including 351 European participants (Graphic: Business Wire) Despite the maturity of the General Data Protection Regulation in Europe, only a third (38%) of European professionals are confident in their organisation’s

Audiencerate Announces Its Partnership With V-Valley21.1.2025 13:00:00 CET | Press release

Audiencerate, an innovative technology company, leader in the development of advanced solutions for digital marketing (MarTech) and online advertising (AdTech) announces that it has signed a partnership agreement with V-Valley, a company of the Esprinet Group focused on the distribution of Advanced Solutions. Thanks to its partnership with Microsoft, Audiencerate is at the forefront of integrating artificial intelligence and cloud computing to optimize marketing and advertising strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250121797053/en/ Thanks to this agreement, V-Valley will make available to its resellers Audiencerate's Marketing Data Platform (MDP), one of the most advanced platforms in the sector, which - thanks to the integration of Microsoft Azure and CoPilot technologies - is able to integrate Artificial Intelligence and cloud computing, optimizing marketing campaigns and providing advanced decision-ma

MBK Partners: Welcoming the Court’s Decision to Prohibit Cumulative Voting for Director Appointments21.1.2025 12:31:00 CET | Press release

Korea Zinc’s Extraordinary General Meeting to Be Conducted Fairly Using a Simple Voting Method MBK Partners and Young Poong, the largest shareholders of Korea Zinc, issue the following statement regarding today’s decision by the Seoul Central District Court’s Civil Division 50 to grant an injunction prohibiting the use of cumulative voting for director appointments at Korea Zinc: MBK Partners and Young Poong welcome the court’s decision to prohibit cumulative voting and view this outcome as a natural and lawful conclusion. The cumulative voting request filed by Yumi Development, for the sole purpose of securing Chairman Yoon Bum Choi’s position, failed to meet the procedural requirements outlined in Article 382-2 of the Korean Commercial Act. The court ruled that while Yumi Development submitted the cumulative voting request on December 10, Korea Zinc’s Articles of Incorporation at that time explicitly stated, “the cumulative voting system shall not apply.” As such, the request violate

Compass Pathways Appoints Steve Levine, M.D., as Chief Patient Officer21.1.2025 12:30:00 CET | Press release

Newly created role of Chief Patient Officer reinforces Compass’ vision of working to achieve broad and equitable access to COMP360, if approved Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental health, today announced the appointment of Steve Levine, M.D., as Chief Patient Officer, effective immediately. In this newly developed executive team role, Dr. Levine will be responsible for ensuring that patient-centric strategies are embedded across the organization and that treatments and initiatives developed by the company are focused on addressing unmet needs in current clinical care and are designed to improve patient outcomes. “Steve has spent the past four years working to deeply understand barriers to care for patients living with serious mental health conditions and he is committed to helping find solutions to address those barriers,” said Kabir Nath, CEO of Compass Pathways. “Steve shares

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye